Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/jac/dkq132 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dynamic analysis of the epidemiology and pathogen distribution of bronchoalveolar lavage fluid in children with severe pulmonary infection: a retrospective study.
Ital J Pediatr
January 2025
Department of Neonatology, Children's Hospital Affiliated to Zhengzhou University, Henan Children's Hospital, Zhengzhou Children's Hospital, Henan, China.
Background: Severe pulmonary infection is the primary cause of death in children aged < 5 years. The early identification of pathogenic bacteria and targeted anti-infective therapies can significantly improve the prognosis of children with severe infections. This study aims to provide a reference for the rational use of antibiotics at an early stage in children with severe pulmonary infections.
View Article and Find Full Text PDFChanges in incidence and epidemiology of antimicrobial resistant pathogens before and during the COVID-19 pandemic in Germany, 2015-2022.
BMC Microbiol
January 2025
Department of Infectious Disease Epidemiology, Robert Koch Institute (RKI), Berlin, Germany.
Background: Carbapenem-resistant Gram-negative bacteria and methicillin-resistant Staphylococcus aureus (MRSA) are among WHO's priority pathogens with antimicrobial resistance (AMR). Studies suggest potential impacts of the COVID-19-pandemic on AMR. We described changes in AMR incidence and epidemiology in Germany during the COVID-19-pandemic.
View Article and Find Full Text PDFEpidemiology of colistin resistance mediated by mcr-1 in carbapenemase-producing Enterobacterales in Ecuador in three periods from 2016 to 2022.
Rev Argent Microbiol
January 2025
Department of Microbiology, School of Medicine and PhD Program in Clinical Medicine and Public Health, University of Granada & Ibs, Granada, Spain; Department of Microbiology, Hospital Virgen de las Nieves, Institute for Biosanitary Research-Ibs, Granada, Spain.
Carbapenemase-producing Enterobacterales (CPE) have increased in the last decade. In low-income countries, colistin is considered a last resort antimicrobial to treat CPE infections, whose most worrisome mechanism of resistance is MCR-1 production. This study aims to understand the epidemiology of colistin resistance in CPE in the region, through the surveillance of the mcr-1 gene in CPE isolates in Ecuador.
View Article and Find Full Text PDFPrevalence, aetiology and antimicrobial resistance profile of diabetic individuals suffering from community-acquired urinary tract infection.
J Med Microbiol
January 2025
Parul Institute of Applied Sciences, Faculty of Applied Sciences, Parul University, Vadodara, Gujarat 391760, India.
The rise in antimicrobial resistance poses a significant threat to global health, particularly among diabetic patients who are prone to urinary tract infections (UTIs). Pathogens that cause UTI among diabetic patients exhibit significant multidrug resistance (MDR) patterns, necessitating more precise empirical treatment strategies..
View Article and Find Full Text PDFRestoring cefepime activity against multidrug-resistant KPC-producing by combination with boronic acid inhibitors, MB076 and S02030.
Antimicrob Agents Chemother
January 2025
Department of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
Foremost in the design of new β-lactamase inhibitors (BLIs) are the boronic acid transition state inhibitors (BATSIs). Two highly potent BATSIs being developed are S02030 and MB076 strategically designed to be active against cephalosporinases and carbapenemases, especially KPC. When combined with cefepime, S02030 and MB076 demonstrated potent antimicrobial activity against laboratory and clinical strains of expressing a variety of class A and class C β-lactamases, including and .
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!